AMEX:VNRX

VolitionRx Signs a Global Sales and Distribution Agreement with Active Motif for its new RUO kits

ISNES, Belgium, May 9, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has entered into a Global Sales and Distribution Agreement with Active Motif for a range of Research Use Only ("RUO") kits, that are based on its proprietary Nucleosomics® tec...

2018-05-09 21:00 723

VolitionRx Limited Schedules First Quarter 2018 Earnings Conference Call and Business Update

Conference call to take place Friday, May 11, 2018 at 8:30 am Eastern time ISNES, Belgium, May 4, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Friday, May 11 at 8:30 a.m. Eastern time to discuss its financial and opera...

2018-05-04 20:00 1228

VolitionRx Announces Closing of $8.4 Million Public Offering of Common Stock

ISNES, Belgium, March 13, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN:  VNRX) ("Volition"), a multi-national life sciences company focused on developing simple, easy to use, cost effective blood tests designed to help diagnose a range of cancers, announced today the closing of its prev...

2018-03-14 04:05 426

VolitionRx Announces Pricing of $8.4 Million Public Offering of Common Stock

ISNES, Belgium, March 9, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national life sciences company focused on developing simple, easy to use, cost effective blood tests designed to help diagnose a range of cancers, announced today...

2018-03-09 22:10 732

VolitionRx Announces Proposed Underwritten Public Offering of Common Stock

NAMUR, Belgium, March 8, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national life sciences company focused on developing simple, easy to use, cost effective blood tests designed to help diagnose a range of cancers, announced t...

2018-03-09 05:01 495

VolitionRx Appoints Harvard Professor, Dr. Lee-Jen Wei to Its Scientific Advisory Board

ISNES, Belgium, March 7, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has further strengthened its Scientific Advisory Board with the addition of Dr.Lee-Jen Wei, a professor of Biostatistics atHarvard University. Prof. Wei's main area of rese...

2018-03-07 21:30 477

VolitionRX Limited Announces Full Fiscal Year 2017 Financial Results and Business Update

Conference call to discuss financial and operational results scheduled for Friday, March 2 at8:30 a.m. Eastern Time ISNES, Belgium, March 1, 2018 /PRNewswire/ -- VolitionRX Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results for the full fiscal year endedDecember 31, 201...

2018-03-02 05:05 714

VolitionRx Limited Schedules Full Year 2017 Earnings Conference Call and Business Update

Conference call to take place Friday, March 2, 2018 at 8:30 am Eastern time ISNES, Belgium, Feb. 28, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE American:  VNRX) today announced it will host a conference call onFriday, March 2 at 8:30 a.m. Eastern time to discuss its financial and operating res...

2018-03-01 05:05 356

VolitionRx Limited Announces Interim Results from 680-Subject Clinical Trial in Colorectal Cancer

* Study demonstrates high detection rates of Stage I cancer and pre-cancerous adenomas in colorectal cancer screening trial for Nu.QTM blood test * Conference call to discuss interim results scheduled for Tuesday, February 27 at 8:30 a.m. Eastern Time ISNES, Belgium, Feb. 26, 2018 /PRNewswire/...

2018-02-27 05:05 373

VolitionRX Announces the Successful Conclusion of the Logistics and Pathway Design Study Conducted in Denmark.

ISNES, Belgium, Feb. 5, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced the successful conclusion to the Logistics and Pathway Design Study conducted by Hvidovre Hospital and The Danish Research Group.  The study was established to answer the very practi...

2018-02-05 21:30 409

VolitionRx Limited Releases Letter to Shareholders Including Status Update on Key Clinical Milestone

ISNES, Belgium, Jan. 3, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today released an important letter from Group CEO,Cameron Reynolds updating the company's shareholders. In the letter, Mr. Reynolds outlines several significant accomplishments to date and highligh...

2018-01-03 21:30 418

VolitionRx Limited to Attend Conferences in December

ISNES, Belgium, Dec. 5, 2017 /PRNewswire/ -- VolitionRx Limited  (NYSE American: VNRX) today announced that its Executive Vice President,Scott Powell, is scheduled to attend two conferences in December. During the conferences, management will outline Volition's busine...

2017-12-05 20:30 392

Singapore Volition signs Memorandum of Understanding with the National Taiwan University to Conduct Two Large Clinical Studies

ISNES, Belgium, Nov. 10, 2017 /PRNewswire/ -- Singapore Volition Pte. Ltd, a wholly-owned subsidiary of VolitionRx Limited (NYSE American: VNRX) ("Volition"), has entered into a Memorandum of Understanding ("MOU") with the National Taiwan University ("NTU") to conduct two large colorectal cancer ...

2017-11-10 20:30 564

VolitionRx Limited Announces Third Quarter 2017 Financial Results and Business Update

ISNES, Belgium, Nov. 9, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) today announced financial results and a business update for the third quarter endedSeptember 30, 2017. Volition management will host a conference call tomorrow,November 10, at 8:30 a.m. U.S. Eastern Time to disc...

2017-11-10 05:05 577

VolitionRx Limited Schedules Third Quarter 2017 Earnings Conference Call and Business Update

Conference call to take place Friday, November 10, 2017 at 8:30 am Eastern time ISNES, Belgium, Nov. 2, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE American:  VNRX) today announced it will host a conference call onFriday, November 10 at 8:30 a.m. Eastern time to discuss its financial and operat...

2017-11-02 20:30 377

VolitionRx Announces the Initial Sale of its New Nu.Q(TM) Research Kits

ISNES, Belgium, Sept. 22, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced its strategy for a new range of Clinical Research Use Only (RUO) kits based on its proprietary Nucleosomics™ technology and the receipt of an order of RUO kits from a large multin...

2017-09-22 20:30 2385

VolitionRx Announces its European Colorectal Cancer Strategy

ISNES, Belgium, Sept. 19, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced its colorectal cancer (CRC) strategy for Europe.  As part of its strategy, Volition plans to select a frontline panel to be validated in two large trials (4,300 and 10,000 sample),...

2017-09-20 04:30 1379

VolitionRx to Attend Two Major Conferences in Asia

ISNES, Belgium, Sept. 15, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will attend Asia Pacific Digestive Week (APDW) and will host a symposium at the Taiwan Digestive Disease Week (TDDW).  Volition's Vice President of Asia, Dr. Jasmine Kway, comm...

2017-09-15 19:30 1530

Volition Granted Four Additional Patents

ISNES, Belgium, Sept. 14, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has been granted four additional patents relating to its proprietary Nu.QTM platform. The newly-issued patents further strengthen Volition's intellectual property portfoli...

2017-09-14 20:00 1106

VolitionRx Limited to Attend Multiple Conferences in September

ISNES, Belgium, Sept. 6, 2017 /PRNewswire/ -- VolitionRx Limited  (NYSE American: VNRX) today announced that its Chief Executive Officer,Cameron Reynolds, its Executive Vice President, Scott Powell, and/or its Chief Medical Officer, Dr. Jason Terrell, are scheduled t...

2017-09-07 04:30 1002
12345